{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:06:21Z","timestamp":1781888781089,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Corneal transplant rejection poses a significant challenge for patients undergoing high-risk penetrating keratoplasty (HR-PKP). We systematically reviewed the literature to evaluate the efficacy of combining topical tacrolimus with steroids in reducing graft failure rates. A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Web of Science and CENTRAL\/Cochrane databases were searched from inception to September 2024. Meta-analyses were conducted using weighted means, proportions and log odds ratios (OR) with a random-effects model. A two-tailed p-value of &lt;0.05 was considered statistically significant. Out of 653 articles identified initially, five homogeneous comparative studies (n\u2009=\u2009274 HR-PKP patients) were included. The tacrolimus-plus-steroids (n\u2009=\u2009138) and steroids-alone (n\u2009=\u2009136) groups were well-matched in baseline characteristics: weighted mean age (54.0 vs. 52.6 years, p\u2009=\u20090.90), sex distribution (p\u2009=\u20090.68), and underlying diagnoses with keratoconus being the most common (29.7% vs. 25.6%, p\u2009=\u20090.68). Follow-up durations were comparable as well (20.1 vs. 20.2 months, p\u2009=\u20090.98). After undergoing HR-PKP, patients in the tacrolimus-plus-steroids group showed significantly reduced graft failure odds by 75.0% (OR: 0.25 [95% CI: 0.13\u20130.43]) compared to patients in the steroids-alone group (p\u2009=\u20090.01). While preserving graft viability in HR-PKP patients remains challenging, adjunctive topical tacrolimus combined with steroids demonstrates a clinically meaningful reduction in graft failure risk. Larger long-term studies are warranted to validate these findings.<\/jats:p>","DOI":"10.1038\/s41433-025-04002-x","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T04:58:11Z","timestamp":1761454691000},"page":"3237-3242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Topical Tacrolimus (FK506) in High-risk Penetrating Keratoplasty: A Systematic Review and Meta-analysis of Comparative Studies"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6691-2665","authenticated-orcid":false,"given":"Jumanah","family":"Qedair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Bawazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,26]]},"reference":[{"key":"4002_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S0161-6420(94)31376-5","volume":"101","author":"A Vail","year":"1994","unstructured":"Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA. Corneal graft survival and visual outcome. A multicenter study. Corneal transplant follow-up study collaborators. Ophthalmology. 1994;101:120\u20137. https:\/\/doi.org\/10.1016\/S0161-6420(94)31376-5.","journal-title":"Ophthalmology"},{"key":"4002_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/0301-4738.91337","volume":"60","author":"S Joshi","year":"2012","unstructured":"Joshi S, Jagdale S, More P, Deshpande M. Outcome of optical penetrating keratoplasties at a tertiary care eye institute in Western India. Indian J Ophthalmol. 2012;60:15\u201321. https:\/\/doi.org\/10.4103\/0301-4738.91337.","journal-title":"Indian J Ophthalmol"},{"key":"4002_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/00003226-200308000-00013","volume":"22","author":"MC Bartels","year":"2003","unstructured":"Bartels MC, Doxiadis IIN, Colen TP, Beekhuis WH. Long-term outcome in high-risk corneal transplantation and the influence of HLA-A and HLA-B matching. Cornea. 2003;22:552\u20136. https:\/\/doi.org\/10.1097\/00003226-200308000-00013.","journal-title":"Cornea"},{"key":"4002_CR4","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0041-1345(99)00010-X","volume":"31","author":"JW Streilein","year":"1999","unstructured":"Streilein JW, Yamada J, Dana MR, Ksander BR. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc. 1999;31:1472\u20135. https:\/\/doi.org\/10.1016\/S0041-1345(99)00010-X.","journal-title":"Transplant Proc"},{"key":"4002_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/ICO.0000000000000258","volume":"33","author":"K Yamazoe","year":"2014","unstructured":"Yamazoe K, Yamazoe K, Yamaguchi T, Omoto M, Shimazaki J. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine. Cornea. 2014;33:1157\u201363. https:\/\/doi.org\/10.1097\/ICO.0000000000000258.","journal-title":"Cornea"},{"key":"4002_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/11206721231172236","volume":"34","author":"L Bernardes","year":"2024","unstructured":"Bernardes L, Gil J, Costa E, et al. Topical tacrolimus in high-risk corneal transplants. Eur J Ophthalmol. 2024;34:140\u20135. https:\/\/doi.org\/10.1177\/11206721231172236.","journal-title":"Eur J Ophthalmol"},{"key":"4002_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.18231\/J.IJCEO.2022.008","volume":"8","author":"V Bhaisare","year":"2022","unstructured":"Bhaisare V, Yadav P, Rawat P, Walia S, Kori N, Gautam M. A comparative study of the effect of topical 0.03% tacrolimus plus 1% topical prednisolone with 1% topical prednisolone alone in preventing rejection after penetrating keratoplasty. Indian J Clin Exp Ophthalmol. 2022;8:36\u201343. https:\/\/doi.org\/10.18231\/J.IJCEO.2022.008.","journal-title":"Indian J Clin Exp Ophthalmol"},{"key":"4002_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/ICO.0000000000002709","volume":"40","author":"K Yu","year":"2021","unstructured":"Yu K, Lian XF, Jiang XY, Zhou SY. Efficacy of immunosuppressants in high rejection risk keratoplasty: a meta-analysis of comparative studies. Cornea. 2021;40:800\u20137. https:\/\/doi.org\/10.1097\/ICO.0000000000002709.","journal-title":"Cornea"},{"key":"4002_CR9","doi-asserted-by":"publisher","unstructured":"Shimazaki J, Tomida D, Yagi-Yaguchi Y, Satake Y, Yamaguchi T. Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial. BMC Ophthalmol. 2024;24. https:\/\/doi.org\/10.1186\/S12886-024-03506-6.","DOI":"10.1186\/S12886-024-03506-6"},{"key":"4002_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ICO.0000000000001408","volume":"37","author":"MN Hashemian","year":"2018","unstructured":"Hashemian MN, Latifi G, Ghaffari R, et al. Topical tacrolimus as adjuvant therapy to corticosteroids in acute endothelial graft rejection after penetrating keratoplasty: a randomized controlled trial. Cornea. 2018;37:307\u201312. https:\/\/doi.org\/10.1097\/ICO.0000000000001408.","journal-title":"Cornea"},{"key":"4002_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2147\/OPTH.S502563","volume":"19","author":"J Aschauer","year":"2025","unstructured":"Aschauer J, Klimek M, Donner R, Steiner I, Lammer J, Schmidinger G. Influential factors and outcome of high-risk keratoplasty in a tertiary referral corneal center: a retrospective study. Clinical Ophthalmol. 2025;19:653\u201362. https:\/\/doi.org\/10.2147\/OPTH.S502563.","journal-title":"Clinical Ophthalmol"},{"key":"4002_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/BJO.86.9.945","volume":"86","author":"JC Hill","year":"2002","unstructured":"Hill JC. High risk corneal grafting. Br J Ophthalmol. 2002;86:945 https:\/\/doi.org\/10.1136\/BJO.86.9.945.","journal-title":"Br J Ophthalmol"},{"key":"4002_CR13","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/ARCHOPHT.1992.01080220054021","volume":"110","author":"The Collaborative Corneal Transplantation Studies (CCTS)","year":"1992","unstructured":"The Collaborative Corneal Transplantation Studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. Archives Ophthalmol. 1992;110:1392\u2013403. https:\/\/doi.org\/10.1001\/ARCHOPHT.1992.01080220054021.","journal-title":"Archives Ophthalmol"},{"key":"4002_CR14","doi-asserted-by":"publisher","unstructured":"Abudou M, Wu T, Evans JR, Chen X. Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty. Cochrane Database Syst Rev. 2015;2015. https:\/\/doi.org\/10.1002\/14651858.CD007603.PUB2.","DOI":"10.1002\/14651858.CD007603.PUB2"},{"key":"4002_CR15","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/S41433-019-0717-3","volume":"34","author":"LY Zhai","year":"2020","unstructured":"Zhai LY, Zhang XR, Liu H, Ma Y, Xu HC. Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study. Eye. 2020;34:1600\u20137. https:\/\/doi.org\/10.1038\/S41433-019-0717-3.","journal-title":"Eye"},{"key":"4002_CR16","doi-asserted-by":"publisher","unstructured":"Qi X, Wang L, Zhang X, Liu M, Gao H. Topical administration of tacrolimus and corticosteroids in tapering doses is effective in preventing immune rejection in high-risk keratoplasty: a 5-year follow-up study. BMC Ophthalmol. 2022;22. https:\/\/doi.org\/10.1186\/S12886-022-02318-W.","DOI":"10.1186\/S12886-022-02318-W"},{"key":"4002_CR17","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/BMJ.N71.","DOI":"10.1136\/BMJ.N71"},{"key":"4002_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/MLR.0000000000000696","volume":"55","author":"BH Chang","year":"2017","unstructured":"Chang BH, Hoaglin DC. Meta-analysis of odds ratios: current good practices. Med Care. 2017;55:328 https:\/\/doi.org\/10.1097\/MLR.0000000000000696.","journal-title":"Med Care"},{"key":"4002_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12874-021-01381-Z\/FIGURES\/5","volume":"21","author":"TH Barker","year":"2021","unstructured":"Barker TH, Migliavaca CB, Stein C, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21:1\u20139. https:\/\/doi.org\/10.1186\/S12874-021-01381-Z\/FIGURES\/5.","journal-title":"BMC Med Res Methodol"},{"key":"4002_CR20","doi-asserted-by":"publisher","unstructured":"Andrade C. Mean difference, standardized mean difference (SMD), and Their use in meta-analysis: as simple as it gets. J Clin Psychiatry. 2020;81. https:\/\/doi.org\/10.4088\/JCP.20F13681.","DOI":"10.4088\/JCP.20F13681"},{"key":"4002_CR21","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/BMJ.D549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:964\u20137. https:\/\/doi.org\/10.1136\/BMJ.D549.","journal-title":"BMJ"},{"key":"4002_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/SIM.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358. https:\/\/doi.org\/10.1002\/SIM.1186.","journal-title":"Stat Med"},{"key":"4002_CR23","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343. https:\/\/doi.org\/10.1136\/BMJ.D4002.","DOI":"10.1136\/BMJ.D4002"},{"key":"4002_CR24","doi-asserted-by":"publisher","unstructured":"Rawat DP. Comparative study of topical tacrolimus with topical cyclosporine therapy on graft survival and visual outcome in penetrating keratoplasty. J Med Sci Clini Res. 2019;7. https:\/\/doi.org\/10.18535\/JMSCR\/V7I4.16.","DOI":"10.18535\/JMSCR\/V7I4.16"},{"key":"4002_CR25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1136\/BJOPHTHALMOL-2013-303639","volume":"97","author":"OA Magalhaes","year":"2013","unstructured":"Magalhaes OA, Marinho DR, Kwitko S. Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. Br J Ophthalmol. 2013;97:1395\u20138. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2013-303639.","journal-title":"Br J Ophthalmol"},{"key":"4002_CR26","unstructured":"OCEBM. Levels of evidence\u2014Centre for Evidence-based Medicine (CEBM), University of Oxford. Accessed July 16, 2023. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."},{"key":"4002_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.11124\/JBIES-22-00224","volume":"21","author":"Z Munn","year":"2023","unstructured":"Munn Z, Stone JC, Aromataris E, et al. Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews. JBI Evid Synth. 2023;21:467\u201371. https:\/\/doi.org\/10.11124\/JBIES-22-00224.","journal-title":"JBI Evid Synth"},{"key":"4002_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.11124\/JBIES-22-00125","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, et al. Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process. JBI Evid Synth. 2023;21:478\u201393. https:\/\/doi.org\/10.11124\/JBIES-22-00125.","journal-title":"JBI Evid Synth"},{"key":"4002_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","volume":"17","author":"AW Thomson","year":"1995","unstructured":"Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17:584\u201391. https:\/\/doi.org\/10.1097\/00007691-199512000-00007.","journal-title":"Ther Drug Monit"},{"key":"4002_CR30","doi-asserted-by":"publisher","unstructured":"Greiner K, Dick AD. Tacrolimus. Intraocular inflammation. Published online May 29, 2023:379\u201384. https:\/\/doi.org\/10.1007\/978-3-540-75387-2_31.","DOI":"10.1007\/978-3-540-75387-2_31"},{"key":"4002_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","volume":"64","author":"AD Mayer","year":"1997","unstructured":"Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the european tacrolimus multicenter renal study group. Transplantation. 1997;64:436\u201343. https:\/\/doi.org\/10.1097\/00007890-199708150-00012.","journal-title":"Transplantation"},{"key":"4002_CR32","doi-asserted-by":"publisher","unstructured":"Penninga L, Penninga EI, M\u00f8ller CH, Iversen M, Steinbr\u00fcchel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev. 2013;2013. https:\/\/doi.org\/10.1002\/14651858.CD008817.pub2.","DOI":"10.1002\/14651858.CD008817.pub2"},{"key":"4002_CR33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(94)93006-6","volume":"344","author":"RH Collins","year":"1994","unstructured":"Collins RH. Tacrolimus (FK506) versus cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344:949.","journal-title":"Lancet"},{"key":"4002_CR34","doi-asserted-by":"publisher","unstructured":"A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation. N Engl J Med. 1994;331:1110\u20135. https:\/\/doi.org\/10.1056\/nejm199410273311702.","DOI":"10.1056\/nejm199410273311702"},{"key":"4002_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/J.DET.2010.03.008","volume":"28","author":"AN Lin","year":"2010","unstructured":"Lin AN. Innovative use of topical calcineurin inhibitors. Dermatol Clin. 2010;28:535\u201345. https:\/\/doi.org\/10.1016\/J.DET.2010.03.008.","journal-title":"Dermatol Clin"},{"key":"4002_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, Van Gelder T, \u00c5sberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41:261\u2013307. https:\/\/doi.org\/10.1097\/FTD.0000000000000640.","journal-title":"Ther Drug Monit"},{"key":"4002_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/BCP.15946","author":"S Udomkarnjananun","year":"2023","unstructured":"Udomkarnjananun S, Eiamsitrakoon T, de Winter BCM, van Gelder T, Hesselink DA. Should we abandon therapeutic drug monitoring of tacrolimus in whole blood and move to intracellular concentration measurements?. Br J Clin Pharmacol. 2023. https:\/\/doi.org\/10.1111\/BCP.15946.","journal-title":"Br J Clin Pharmacol"},{"key":"4002_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.733285","volume":"12","author":"BC Sallustio","year":"2021","unstructured":"Sallustio BC. Monitoring Intra-cellular tacrolimus concentrations in solid organ transplantation: use of peripheral blood mononuclear cells and graft biopsy tissue. Front Pharmacol. 2021;12:733285. https:\/\/doi.org\/10.3389\/fphar.2021.733285.","journal-title":"Front Pharmacol"},{"key":"4002_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.5500\/WJT.V13.I5.254","volume":"13","author":"MC Morais","year":"2023","unstructured":"Morais MC, Soares ME, Costa G, et al. Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation. World J Transplant. 2023;13:254\u201363. https:\/\/doi.org\/10.5500\/WJT.V13.I5.254.","journal-title":"World J Transplant"},{"key":"4002_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/TP.0000000000003350","volume":"105","author":"SC Ong","year":"2021","unstructured":"Ong SC, Gaston RS. Thirty years of tacrolimus in clinical practice. Transplantation. 2021;105:484\u201395. https:\/\/doi.org\/10.1097\/TP.0000000000003350.","journal-title":"Transplantation"},{"key":"4002_CR41","doi-asserted-by":"publisher","unstructured":"SH A. Topical tacrolimus in anterior segment disorders in ophthalmology: a review. Rom J Ophthalmol. 2024;68. https:\/\/doi.org\/10.22336\/RJO.2024.19.","DOI":"10.22336\/RJO.2024.19"},{"key":"4002_CR42","doi-asserted-by":"publisher","unstructured":"Shoughy SS. Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis. 2017;4. https:\/\/doi.org\/10.1186\/S40662-017-0072-Z.","DOI":"10.1186\/S40662-017-0072-Z"},{"key":"4002_CR43","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/J.MEHY.2013.08.007","volume":"81","author":"V Garg","year":"2013","unstructured":"Garg V, Jain GK, Nirmal J, Kohli K. Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis. Med Hypotheses. 2013;81:901\u20134. https:\/\/doi.org\/10.1016\/J.MEHY.2013.08.007.","journal-title":"Med Hypotheses"},{"key":"4002_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/EJHPHARM-2020-002447","volume":"29","author":"M Zhao","year":"2022","unstructured":"Zhao M, He F, Yang Y, et al. Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials. Eur J Hosp Pharm. 2022;29:129\u201333. https:\/\/doi.org\/10.1136\/EJHPHARM-2020-002447.","journal-title":"Eur J Hosp Pharm"},{"key":"4002_CR45","unstructured":"The Use of Tacrolimus in High-Risk Penetrating Keratoplasty\u2014American Academy of Ophthalmology. 2025. https:\/\/www.aao.org\/education\/current-insight\/use-of-tacrolimus-in-highrisk-penetrating-keratopl Accessed 16 Jun 2025."},{"key":"4002_CR46","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/S41433-021-01855-W","volume":"36","author":"SL Painter","year":"2022","unstructured":"Painter SL, Rana M, Barua A, et al. Outcomes following tacrolimus systemic immunosuppression for penetrating keratoplasty in infants and young children. Eye (Lond). 2022;36:2286\u201393. https:\/\/doi.org\/10.1038\/S41433-021-01855-W.","journal-title":"Eye (Lond)"},{"key":"4002_CR47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/ICO.0000000000003316","volume":"43","author":"TM Tran","year":"2024","unstructured":"Tran TM, Azher TN, Miller CJ, Hou JH. Topical tacrolimus compared with oral tacrolimus for postoperative immunosuppression in primary keratolimbal allograft. Cornea. 2024;43:333\u201342. https:\/\/doi.org\/10.1097\/ICO.0000000000003316.","journal-title":"Cornea"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04002-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04002-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04002-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:39:15Z","timestamp":1764599955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04002-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":47,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4002"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04002-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,26]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}